Lijing Zhu
No. 155, Hanzhong Road
Nanjing, 210029, China
Nanjing, 210029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Low-dose radiotherapy combined with immune checkpoint inhibitors in advanced malignancies: a real-world exploratory study.
Journal: Translational cancer research
Published: March 26, 2026
Evaluation of large language models in female malignancy Q&A.
Journal: Medicine
Published: June 02, 2025
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.
Journal: Nature communications
Published: April 21, 2025
Bifunctional Phage Particles Augment CD40 Activation and Enhance Lymph Node-Targeted Delivery of Personalized Neoantigen Vaccines.
Journal: ACS nano
Published: February 11, 2025
Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy.
Journal: Nature communications
Published: October 29, 2024
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.
Journal: Med (New York, N.Y.)
Published: October 22, 2024
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Journal: Lancet (London, England)
Published: August 28, 2024
Intranodal injection of neoantigen-bearing engineered Lactococcus lactis triggers epitope spreading and systemic tumor regressions.
Journal: Acta pharmaceutica Sinica. B
Published: August 20, 2024
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: 'R-ISV-FOLactis' trial.
Journal: Future oncology (London, England)
Published: July 22, 2024
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Journal: The Lancet. Oncology
Published: May 18, 2023
Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.
Journal: Frontiers in immunology
Published: January 11, 2023
Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
Journal: Human vaccines & immunotherapeutics
Published: April 25, 2022
Last Updated: 09/26/2026